Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $118.0 million.

  • Roivant Sciences' Accumulated Expenses rose 1310.05% to $118.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $118.0 million, marking a year-over-year increase of 1310.05%. This contributed to the annual value of $114.3 million for FY2025, which is 429.0% down from last year.
  • Roivant Sciences' Accumulated Expenses amounted to $118.0 million in Q4 2025, which was up 1310.05% from $108.3 million recorded in Q3 2025.
  • Roivant Sciences' 5-year Accumulated Expenses high stood at $167.1 million for Q1 2023, and its period low was $73.8 million during Q2 2021.
  • Over the past 5 years, Roivant Sciences' median Accumulated Expenses value was $116.1 million (recorded in 2025), while the average stood at $116.5 million.
  • As far as peak fluctuations go, Roivant Sciences' Accumulated Expenses skyrocketed by 6576.25% in 2022, and later tumbled by 3583.83% in 2025.
  • Roivant Sciences' Accumulated Expenses (Quarter) stood at $112.7 million in 2021, then grew by 17.47% to $132.4 million in 2022, then decreased by 7.71% to $122.1 million in 2023, then fell by 14.59% to $104.3 million in 2024, then rose by 13.1% to $118.0 million in 2025.
  • Its Accumulated Expenses was $118.0 million in Q4 2025, compared to $108.3 million in Q3 2025 and $88.7 million in Q2 2025.